Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global company in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences. This news page aggregates announcements, press releases, and corporate updates related to Waters, giving readers a focused view of developments that affect the company and its markets.
Investors and industry professionals can use this feed to follow Waters’ product launches, financial results, and strategic initiatives. Recent news has highlighted new technologies such as the Xevo Charge Detection Mass Spectrometer (CDMS), which Waters describes as enabling direct mass detection for large biomolecules relevant to next-generation therapeutics, and a Charged Aerosol Detector designed for use with the company’s Empower chromatography data system. These announcements illustrate how Waters is addressing analytical challenges in pharmaceuticals, biotherapeutics, food analysis, and environmental testing.
The news stream also features quarterly earnings releases, where Waters reports sales performance, instrument and recurring revenue trends, and commentary from management. In addition, Waters issues updates on investor conference presentations and on the planned combination with BD’s Biosciences & Diagnostic Solutions business via a Reverse Morris Trust transaction, as described in its press releases and Form 8-K filings.
By reviewing Waters-related news in one place, readers can track themes such as instrument replacement cycles, adoption of new chromatography and mass spectrometry products, and the company’s expansion into adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics. Bookmark this page to monitor ongoing disclosures and media releases that shape the narrative around WAT stock and Waters’ role in regulated, high-volume testing and scientific markets.
Summary not available.
Waters Corporation (NYSE:WAT) will announce its Q1 2023 financial results on May 9, 2023, at 8:00 a.m. Eastern Time. A live webcast will be accessible through the company’s investor relations website, with a replay available until May 23, 2023. Waters Corporation has a rich history of over 60 years in analytical instruments, including chromatography and mass spectrometry, and operates in more than 35 countries with over 8,200 employees globally.
Waters Corporation (NYSE:WAT) has launched the Xevo TQ Absolute IVD System, enhancing its MassTrak IVD portfolio. This state-of-the-art system is the most sensitive benchtop tandem quadrupole mass spectrometer for clinical applications, boasting up to five times the sensitivity of its peers. It features a 45% smaller design and consumes 50% less nitrogen gas and electricity, making it environmentally sustainable. The Xevo TQ Absolute IVD allows laboratories to analyze trace-level analytes in smaller samples, thereby expanding testing capabilities for less-invasive assays. The system aims to improve patient care through advanced diagnostic options.
Waters Corporation (NYSE:WAT) has appointed Richard Fearon to its Board of Directors, effective March 27, 2023. Fearon, former Vice Chairman and Chief Financial Officer of Eaton Corporation, is expected to bring financial expertise and strategic development skills to enhance Waters' growth plan. CEO Udit Batra noted that Fearon's leadership experience will strengthen Waters' competitive position. This change follows the retirement of Edward Conard, who has served on the board since 1994, contributing to an 80-fold stock increase over nearly 30 years. The board will now consist of nine members, with three new appointees over the past year.
Waters Corporation (NYSE:WAT) has launched its Alliance iS High Performance Liquid Chromatography (HPLC) System, designed to enhance quality control in laboratories by reducing common errors by up to 40%. This next-generation system integrates with Empower Chromatography Software and eConnect HPLC Columns, promoting operational risk management and productivity. Featuring an intuitive touchscreen for guided operation and system health monitoring, it helps laboratories meet compliance and product delivery goals. The Alliance iS HPLC System will be available starting May 2023.
Waters Corporation (NYSE: WAT) has launched the Battery Cycler Microcalorimeter Solution, enabling unprecedented battery testing capabilities. This advanced device collects six times more data than competitors and reduces validation time for battery safety and performance by up to 75%. The solution allows simultaneous testing of 12 batteries, enhancing efficiency in battery research. With integrated software, researchers can accurately analyze experiments in real-world conditions, optimizing battery development.
Waters Corporation (NYSE:WAT) has ranked fifth on Barron’s 2023 100 Most Sustainable Companies list, marking its third consecutive year on the list and its second in the top ten. The company emphasizes its commitment to environmental, social, and governance (ESG) goals, including reducing its environmental impact and enhancing workforce diversity. Notable achievements in 2022 included the introduction of the Xevo™ TQ Absolute mass spectrometer, which uses 50% less energy and emits less heat, and the opening of a $215 million Precision Chemistry facility in Taunton, Massachusetts, recognized as LEED-certified.
Waters Corporation (NYSE:WAT) announced that its President and CEO, Udit Batra, will take part in a fireside chat at the Cowen Healthcare Conference on March 6, 2023, at 9:50 AM Eastern Time. A live webcast will be accessible via Waters’ investor relations website, and a replay will be available for 30 days after the event. Waters Corporation is a leader in analytical instruments and software, specializing in chromatography, mass spectrometry, and thermal analysis, with over 8,200 employees globally and operations in more than 35 countries.
Waters Corporation (NYSE: WAT) reported fourth-quarter 2022 sales of $859 million, reflecting a 3% increase as reported and 9% in constant currency compared to Q4 2021. The full-year 2022 sales reached $2.97 billion, up 7% as reported and 12% in constant currency. Diluted EPS rose to $3.81 in Q4 2022 from $3.52 in Q4 2021. The company anticipates 2023 organic sales growth of 5% to 6.5% and non-GAAP EPS between $12.55 and $12.75, including a 3% foreign exchange headwind. Additionally, Waters announced the acquisition of Wyatt Technology for $1.36 billion, expected to close in Q2 2023, which will enhance its growth strategy.
Waters Corporation (NYSE:WAT) has announced the acquisition of Wyatt Technology for $1.36 billion. This strategic move is aimed at enhancing Waters’ growth by expanding its presence in high-growth adjacent markets, particularly in bioanalytical characterization related to cell and gene therapies. The acquisition is expected to be accretive to revenue and adjusted earnings per share starting Q1 2024, with projected revenue synergies exceeding $70 million by year five. Wyatt, with 2022 revenues of $110 million, brings significant expertise in light scattering technology, further bolstering Waters' analytical solutions portfolio.